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Long noncoding RNAs (lncRNAs) constitute the majority of transcripts in the mammalian genomes, and yet, their func-
tions remain largely unknown. As part of the FANTOM6 project, we systematically knocked down the expression of
285 lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic re-
sponses using Capped Analysis of Gene Expression (CAGE). Antisense oligonucleotides targeting the same lncRNAs exhib-
ited global concordance, and the molecular phenotype, measured by CAGE, recapitulated the observed cellular
phenotypes while providing additional insights on the affected genes and pathways. Here, we disseminate the largest-to-
date lncRNA knockdown data set with molecular phenotyping (over 1000 CAGE deep-sequencing libraries) for further
exploration and highlight functional roles for ZNF213-AS1 and lnc-KHDC3L-2.
[Supplemental material is available for this article.]
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Over 50,000 loci in the human genome transcribe long noncoding
RNAs (lncRNAs) (Iyer et al. 2015; Hon et al. 2017), which are de-
fined as transcripts at least 200 nucleotides (nt) long with low or
no protein-coding potential. Although lncRNA genes outnumber
protein-coding genes in mammalian genomes, they are compara-
tively less conserved (Ulitsky 2016), lowly expressed, and more
cell-type-specific (Hon et al. 2017). However, the evolutionary
conservation of lncRNA promoters (Carninci et al. 2005) and the
structural motifs of lncRNAs (Chu et al. 2015; Xue et al. 2016)
suggest that lncRNAs are fundamental biological regulators. To
date, only a few hundred human lncRNAs have been extensively
characterized (de Hoon et al. 2015; Quek et al. 2015; Volders
et al. 2015; Ma et al. 2019), revealing their roles in regulating tran-
scription (Engreitz et al. 2016b), translation (Carrieri et al. 2012),
and chromatin state (Gupta et al. 2010; Guttman et al. 2011;
Guttman and Rinn 2012; Quinn and Chang 2016; Ransohoff
et al. 2018).
Our recent FANTOM5 computational analysis showed that
19,175 (out of 27,919) human lncRNA loci are functionally impli-
cated (Hon et al. 2017). Yet, genomic screens are necessary to com-
prehensively characterize each lncRNA.One common approach of
gene knockdown followed by a cellular phenotype assay typically
characterizes a small percentage of lncRNAs for a single observable
phenotype. For example, a recent large-scale screening using
CRISPR interference (CRISPRi) found that ∼3.7% of targeted
lncRNA loci are essential for cell growth or viability in a cell-type-
specific manner (Liu et al. 2017). In addition, CRISPR-Cas9 experi-
ments targeting splice sites identified∼2.1%of lncRNAs that affect
growth of K562 (Liu et al. 2018), and a CRISPR activation study re-
vealed∼0.11% lncRNAs to be important for drug resistance inmel-
anoma (Joung et al. 2017). However, many of these studies target
the genomic DNA, potentially perturbing the chromatin architec-
ture, or focus on a single cellular assay, possiblymissing other rele-
vant functions and underlying molecular pathways.
As a part of the FANTOM6 pilot project, we established an au-
tomated high-throughput cell culture platform to suppress 285
lncRNAs expressed in human primary dermal fibroblasts (HDFs)
using antisense LNA-modified GapmeR antisense oligonucleotide
(ASO) technology (Roux et al. 2017).We then quantified the effect
of each knockdown on cell growth and morphology using real-
time imaging, followed by Cap Analysis Gene Expression (CAGE)
(Murata et al. 2014) deep sequencing to revealmolecular pathways
associated with each lncRNA. In contrast to cellular phenotyping,
molecular phenotyping provides a detailed assessment of the re-
sponse to a lncRNA knockdown at themolecular level, allowing bi-
ological pathways to be associated to lncRNAs even in the absence
of an observable cellular phenotype. All data and analysis results
are publicly available (see Data access), and results can be interac-
tively explored using our in-house portal (https://fantom.gsc.riken
.jp/zenbu/reports/#FANTOM6).
Results
Selection and ASO-mediated knockdown of lncRNA targets
Human dermal fibroblasts are nontransformed primary cells that
are commonly used for investigating cellular reprogramming
(Takahashi et al. 2007; Ambasudhan et al. 2011), wound healing
(Li and Wang 2011), fibrosis (Kendall and Feghali-Bostwick
2014), and cancer (Kalluri 2016). Here, an unbiased selection of
lncRNAs expressed in HDFs was performed to choose 285
lncRNAs for functional interrogation (Methods; Supplemental
Table S1; Fig. 1A–C). Using RNA-seq profiling of fractionated
RNA, we annotated the lncRNA subcellular localization as the
chromatin-bound (35%), nucleus-soluble (27%), or cytoplasmic
(38%) (Fig. 1D). We then designed a minimum of five non-over-
lapping antisense oligonucleotides against each lncRNA (Supple-
mental Methods; Supplemental Table S2; Fig. 1E,F) and
transfected them individually using an automated cell culture
platform to minimize experimental variability (Fig. 1G). The
overall knockdown efficiencies across 2021 ASOs resulted in me-
dian value of 45.4%, and we could successfully knockdown 879
out of 2021 (43.5%) ASOs (>40% knockdown efficiency in at least
two primer pairs or >60% in one primer pair) (Supplemental Ta-
ble S2). ASOs targeting exons or introns were equally effective,
and knockdown efficiencies were independent of the genomic
class, expression level, and subcellular localization of the lncRNA
(Supplemental Fig. S1A–D).
A subset of lncRNAs are associated with cell growth
and morphology changes
To evaluate the effect of each lncRNA knockdown on cell growth
and morphology, we imaged ASO-transfected HDFs in duplicate
every 3 h for a total of 48 h (Supplemental Table S3) and estimat-
ed their growth rate based on cell confluence measurements (Fig.
2A,B). First, we observed across all ASOs that changes in cell
growth and morphological parameters were significantly correlat-
ed with knockdown efficiency (Supplemental Fig. S1E). Consider-
ing both successful knockdown and significant growth inhibition
(Student’s two-sided t-test FDR≤0.05), 246 out of 879 ASOs
(∼28%) showed cellular phenotype (Fig. 2C; Supplemental Table
S3).
To assess globally whether the observed growth inhibition is
lncRNA-specific, we used all 194 lncRNAs successfully targeted by
at least two ASOs (Supplemental Fig. S2A) and found that ASOs tar-
geting the same lncRNA were significantly more likely to have a
concordant growth response than ASOs targeting different
lncRNA (empirical P=0.00037) (Supplemental Methods; Supple-
mental Fig. S2B). However, different ASOs targeting the same
lncRNA typically showed different effects on growth, possibly
due to variable knockdown efficiencies or differences in targeted
lncRNA isoforms, as well as off-target effects. To reliably identify
target-specific cellular phenotype, we applied conditional cutoffs
based on the number of successful ASOs per each lncRNA (Supple-
mental Methods; Supplemental Fig. S2C) and identified 15/194
lncRNAs (7.7%) with growth phenotype (adjusted background
<5%) (Supplemental Fig. S2D). We validated A1BG-AS1, which
was previously implicated in cell growth (Bai et al. 2019),
CATG00000089639, RP11-195F19.9, and ZNF213-AS1 by measur-
ing theMKI67 proliferation proteinmarker upon knockdownwith
siRNAs and with selected ASOs (Fig. 2D; Supplemental Fig. S2E).
In addition to cell growth, we also explored changes in cell
morphology (Fig. 2E). Using amachine learning-assisted workflow
(Methods), each cell was segmented and itsmorphological features
representing various aspects of cell shapes and sizes were quanti-
fied (Fig. 2F; Supplemental Table S3; Carpenter et al. 2006). As
an example, knockdown of 14/194 lncRNAs (7.2%) affected the
spindle-likemorphology of fibroblasts, as indicated by a consistent
decrease in their observed eccentricity without reducing the cell
number, suggesting possible cellular transformation toward epi-
thelial-like states. Collectively, we observed 59/194 lncRNAs
(∼30%) affecting cell growth and/or morphological parameters
(Fig. 2G; Supplemental Table S3).
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Molecular phenotyping by CAGE recapitulates cellular
phenotypes and highlights functions of lncRNAs
Next, we selected 340 ASOs with high knockdown efficiencies
(mostly >50%; median 71.4%) and sequenced 970 CAGE libraries
to analyze 154 lncRNAs (Fig. 3A; Supplemental Table S4). To assess
functional implications by individual ASOs, we performed differ-
ential gene expression, Motif Activity Response Analysis (MARA)
(The FANTOMConsortium et al. 2009), and Gene Set Enrichment
Analysis (GSEA) (Fig. 3B–F; Subramanian et al. 2005), and com-
pared them with cellular phenotype.
We globally observed significant knockdown-mediated tran-
scriptomic changes (which generally correlated with KD efficiency)
(Supplemental Fig. S3A),with∼57%ofASOs showing at least 10 dif-
ferentially expressed genes (FDR≤0.05; abs[log2FC] >0.5). For 84
divergent-antisense lncRNAs (targeted by 186 independent ASOs)
(SupplementalMethods),we found their partner gene to be general-
ly unchanged (median abs[log2FC] =∼0.13), with an exception of
two significantly down-regulated and three significantly up-regulat-
ed genes (FDR≤0.05) (Supplemental Fig. S3B). We have, however,
noticed a common response in a large number of ASOs (∼30%–
35% of all responding ASOs), such as down-regulation of cell-
cycle-related pathways, up-regulated stress genes and pathways, or
altered cell metabolism and energetics (Supplemental Fig. S3C,D).
When comparing knockdown-mediatedmolecular and cellu-
lar response, we found that transcription factor motifs that
E
F
BA C
D
G
Figure 1. Selectionof lncRNA targets, their properties, and the studyoverview. (A) CAGEexpression levels at log2TPM(tagspermillion) andhumandermal
fibroblasts (HDFs) specificity of lncRNAs in the FANTOMCAT catalog (Hon et al. 2017) (N=62,873; gray), lncRNAs expressed in HDFs (N=6125; blue), and
targeted lncRNAs (N=285; red). The dashed vertical line indicatesmost lowly expressed lncRNA target (∼0.2 TPM). (B) Gene conservation levels of lncRNAs
in the FANTOMCAT catalog (gray), lncRNAs expressed in HDFs (blue), and targeted lncRNAs (red). Crossbars indicate themedian. No significant difference
is observedwhen comparing targeted and expressed inHDF lncRNAs (Wilcoxon P=0.11). (C ) Similar to that in Bbut for genomic classes of lncRNAs.Most of
the targeted lncRNAs and those expressed in HDFs are expressed fromdivergent promoters. (D) Subcellular localization (based on relative abundances from
RNA-seq fractionation data) for targeted lncRNAs. Chromatin-bound (N=98; blue); nuclear soluble (N=76; green); cytoplasmic (N=108; red). Black con-
tours represent thedistributionof all lncRNAs expressed inHDFs. (E) Example ofZNF213-AS1 loci showing transcriptmodel, CAGE, andRNA-seq signal along
with targeting ASOs. (F) Number of ASOs for target lncRNAs and controls used in the experiment. (G) Schematics of the study.
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promote cell growth, including TFDP1, E2F1,2,3, and EP300, were
positively correlated with the measured cell growth rate, whereas
transcription factor motifs known to inhibit growth or induce
apoptosis (e.g., PPARG, SREBPF, and STAT2,4,6) were negatively
correlated (Fig. 3D; Supplemental Fig. S4A; Supplemental Table
S6). Moreover, correlations of growth with GSEA pathways (Fig.
3F; Supplemental Fig. S4B; Supplemental Table S6) or with
FANTOM5 coexpression clusters (Supplemental Fig. S4C) showed
that cell growth and replication-related pathways were positively
correlated with the measured growth rate, whereas those related
E
F
BA C
D G
Figure 2. Cell growth and morphology assessment. (A) Selected example (PTPRG1-AS1) showing the normalized growth rate estimation using a match-
ing NC_A (negative control). (B) Correlation of the normalized growth rate for technical duplicates across 2456 Incucyte samples. (C) Density distribution
of normalized growth rates (technical replicates averaged) 252 ASOs targeting lncRNAs with successful knockdown (KD) and growth phenotype (blue)
consistent in two replicates (FDR <0.05 as compared to matching NC_A; 246 ASOs inhibited growth), 627 ASOs targeting lncRNAs with successful KD
(purple), 270 negative control (NC_A) samples (gray), and 90 mock-transfected cells (Lipofectamine only) samples (yellow). (D) MKI67 staining (growth
inhibition validation) for four selected lncRNA targets after siRNA and ASOs suppression. (E) Incucyte cell images of selected distinct cell morphologies
changes upon an lncRNA KD. (F) An overview of the cell morphology imaging processing pipeline using a novel lncRNA target, CATG000089639.1, as
an example. (G) lncRNAs (N=59) significantly (FDR <0.05) and consistently (after adjusting for the number of successfully targeting ASOs) affecting
cell growth (N=15) and cell morphologies (N=44).
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to immunity, and cell stress and cell deathwere negatively correlat-
ed. We found that among 53 ASOs implicated in a growth-inhibi-
tion pathway based on the CAGE profiles, only 43% of them
showed growth inhibition in the real-time imaging. This might
suggest better sensitivity of transcriptomic profiling when detect-
ing phenotypes as compared to live cell imaging methods, which
are more prone to a delayed cellular response to the knockdown.
Additionally, morphological changes were reflected in the
molecular phenotype assessed by CAGE (Supplemental Fig. S4D).
Cell radius and axis length were associat-
ed with GSEA categories related to actin
arrangement and cilia, whereas cell com-
pactness was negatively correlated with
apoptosis. The extensive molecular phe-
notyping analysis also revealed pathways
not explicitly associated with cell growth
and cell morphology, such as transcrip-
tion, translation, metabolism, develop-
ment, and signaling (Fig. 3E).
Next, to globally assess whether in-
dividual ASO knockdowns lead to
lncRNA-specific effects, we scaled the ex-
pression change of each gene across the
whole experiment and compared differ-
entially expressed genes (Fig. 3B) of all
possible ASO pairs targeting the same
lncRNA target versus different lncRNAs
(Supplemental Methods; Supplemental
Table S5). We found that the concor-
dance of the same target group was sig-
nificantly greater than that of the
different target group (comparing the
Jaccard indices across 10,000 permuta-
tions) (Supplemental Fig. S5A), suggest-
ing that ASO knockdowns are
nonrandom and lead to more lncRNA
specific effects than the nontargeting
ASO pairs. Further, by requiring at least
five common DEGs (FDR≤0.05, abs
[log2FC] > 0.5, abs[Z-score] > 1.645) and
ASO-pairs significantly above the non-
targeting ASO pairs background (P≤
0.05), we identified 16 ASO pairs, target-
ing 13 lncRNAs, exhibiting reproducible
knockdown-mediated molecular re-
sponses in human dermal fibroblasts
(Supplemental Fig. S5B). Corresponding
GSEA pathways and MARA motifs of
these 16 ASO pairs are shown in
Supplemental Figure S5C.
siRNA validation experiments
To evaluate whether the lncRNA-specific
effects can be measured by other knock-
down technologies, nine lncRNAs, with
relatively mild growth phenotype, were
subjected to siRNA knockdown. Measur-
ing transcriptional response, we noted
that higher concordance was observed
for ASO modality alone (Supplemental
Fig. S5D). The observed discrepancies in
the transcriptional response between ASO- and siRNA-mediated
knockdowns could be contributed by theirmode of action and var-
iable activities in different subcellular compartments. Next, a con-
cordant response was found for (5/36) ASO-siRNA pairs targeting
three lncRNAs (Supplemental Fig. S5E; Supplemental Table S5),
enriched in the cytoplasm (MAPKAPK5-AS1), soluble nuclear
fraction (LINC02454), and in the chromatin-bound fraction
(A1BG-AS1). Although we cannot completely exclude the techni-
cal artifacts of each technology, concordant cellular response
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Figure 3. CAGE predicts cellular phenotypes. (A) RT-qPCR knockdown efficiency for 2021 ASO-trans-
fected samples (targeted lncRNAs only). Gray dashed line indicates 50% KD efficiency generally required
for CAGE selection. Purple dashed lines indicate median KD efficiency (71.5%) for 375 ASOs selected for
CAGE sequencing. After quality control, 340 ASOs targeting lncRNAs were included for further analysis.
(B) Distribution of significantly differentially expressed genes (up-regulated: FDR<0.05, Z-score > 1.645,
log2FC>0.5; and down-regulated: FDR<0.05, Z-score <−1.645, log2FC<−0.5) across all 340 ASOs. (C)
Motif Response Activity Analysis (MARA) across 340 ASOs. Scale indicates Z-score of the relative motif ac-
tivity (the rangewas set to abs[Z-score] = <5 for visualization purposes). (D) Correlation between normal-
ized growth rate and motif activities across 340 ASOs targeting lncRNAs with highlighted examples.
Motif sizes shown are scaled based on the HDF expression of their associated TFs (range 1 to ∼600
TPM). (E) Enriched biological pathways across 340 ASOs. Scale indicates GSEA enrichment value calcu-
lated as−log10(p) × sign(NES). (F ) Same as inD but for selected GSEA pathways. Pathways sizes are scaled
based on the number of associated genes.
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exhibited by using ASOs alone suggests that lncRNAs, in part, are
essential regulatory elements in cells. Yet, our study generally war-
rants a careful assessment of specific findings from different
knockdown technologies, including CRISPR-inhibition, and dem-
onstrates a requirement of using multiple replicates in a given tar-
get per each modality.
ZNF213-AS1 is associated with cell growth and migration
Extensive molecular and cellular phenotype data for each ASO
knockdown can be explored using our portal https://fantom.gsc
.riken.jp/zenbu/reports/#FANTOM6. As an example of an lncRNA
associatedwithcell growthandmorphology (Fig. 2G),weshowcase
ZNF213-AS1 (RP11-473M20.14). This lncRNA is highly conserved
in placental mammals, moderately expressed (∼eight CAGE tags
per million) in HDFs, and enriched in the chromatin-bound frac-
tion. Four distinct ASOs (ASO_01, ASO_02, ASO_05, and ASO_06)
strongly suppressedexpressionofZNF213-AS1,whereas expression
of the ZNF213 sense gene was not significantly affected in any of
the knockdowns. The four ASOs caused varying degrees of cell
growth inhibition (Fig. 4A). ASO_01 and ASO_06 showed a reduc-
tion in cell number, aswell as anup-regulationof apoptosis and im-
mune and defense pathways in GSEA, suggesting cell death.While
cell growth inhibition observed for ASO_02 and ASO_05 was con-
firmed by MKI67 marker staining (Fig. 2D; Supplemental Table
S7), the molecular phenotype revealed suppression of GSEA path-
ways related to cell growth, as well as to cell proliferation, motility,
and extracellular structure organization (Fig. 4B).We also observed
consistent down-regulation ofmotifs related to the observed cellu-
lar phenotype, for example, EGR1, EP300, SMAD1…7,9 (Fig. 4C).
As cellmotility pathwayswere affected by the knockdown,we
tested whether ZNF213-AS1 could influence cell migration. Based
on the wound-closure assay after transient cell growth inhibition
(mitomycin C and serum starvation) (Supplemental Fig. S2F,G),
we observed a substantial reduction of wound closure rate (∼40%
over a 24-h period) in the ZNF213-AS1-depleted HDFs (Fig. 4D,
E). The reduced wound healing rate should thus mainly reflect re-
duced cell motility, further confirming affected motility pathways
predicted by the molecular phenotype.
As these results indicated a potential role of ZNF213-AS1 in
cell growth and migration, we used FANTOM CAT Recount 2 at-
las (Imada et al. 2020), which incorporates The Cancer Genome
Atlas (TCGA) data set (Collado-Torres et al. 2017), and found rel-
atively higher expression of ZNF213-AS1 in acute myeloid leuke-
mia (LAML) and in low-grade gliomas (LGG) as compared to
other cancers (Supplemental Fig. S6A). In LAML, the highest ex-
pression levels were associated with mostly undifferentiated
states, whereas in LGG, elevated expression levels were found
in oligodendrogliomas, astrocytomas, and in IDH1 mutated tu-
mors, suggesting that ZNF213-AS1 is involved in modulating
E
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Figure 4. ZNF213-AS1 regulates cell growth, migration, and proliferation. (A) Normalized growth rate across four distinct ASOs (in duplicate) targeting
ZNF213-AS1 as compared to six negative control samples (shown in gray). (B) Enrichment of biological pathways associated with growth, proliferation,
wound healing, migration, and adhesion for ASO_02 and ASO_05. (C) Most consistently down- and up-regulated transcription factor binding motifs in-
cluding those for transcription factors known to modulate growth, migration, and proliferation such as for example EGR family, EP300, GTF2I.
(D) Knockdown efficiency measured by RT-qPCR after wound closure assay (72 h posttransfection) showing sustained suppression (65%–90%) of
ZNF213-AS1. (E) Transfected, replated, and mitomycin C (5 µg/mL)-treated HDF cells were scratched and monitored in the Incucyte imaging system.
Relative wound closure rate calculated during the 24 h postscratching shows 40%–45% reduction for the two targeting ASOs (ASO_02 [N=10] and
ASO_05 [N=13]) as compared to NC_A transfection controls (N=33, shown in gray) and the representative images of wound closure assay 16 h
postscratching.
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differentiation and proliferation of tumors (Supplemental Fig.
S6B–E). Further, univariate Cox proportional hazard analysis as
well as Kaplan-Meier curves for LGG were significant and consis-
tent with our findings (HR=0.61, BH FDR=0.0079). The same
survival analysis on LAML showed a weak association with
poor prognostic outcome, but the results were not significant
(Supplemental Fig. S6F,G).
RP11-398K22.12 (KHDC3L-2) regulates KCNQ5 in cis
Next, we investigated in detail RP11-398K22.12 (ENSG00000229
852), where the knockdowns by two independent ASOs
(ASO_03, ASO_05) successfully reduced the expression of the tar-
get lncRNA (67%–82% knockdown efficiency, respectively) and
further down-regulated its neighboring genes, KCNQ5 and its
divergent partner novel lncRNA CATG00000088862.1 (Fig. 5A).
Although the two genomic loci occupy Chromosome 6 and
are 650 kb away, Hi-C analysis (Supplemental Methods; Supple-
mental Fig. S7; Supplemental Table S8) showed that they are locat-
ed within the same topologically associated domain (TAD) and
spatially colocalized (Fig. 5B). Moreover, chromatin-enrichment
and single molecule RNA-FISH of RP11-398K22.12 (Fig. 5C;
Supplemental Table S9) suggested its highly localized cis-regulato-
ry role.
In FANTOM5 (Hon et al. 2017), expression levels of RP11-
398K22.12, KCNQ5, and CATG00000088862.1 were enriched in
brain and nervous system samples, whereas GTEx (The GTEx
Consortium 2015) showed their highly specific expression in the
brain, particularly in the cerebellumand the cerebellar hemisphere
(Fig. 5D). GTEx data also showed that expression of RP11-
398K22.12 was highly correlated with the expression of KCNQ5
and CATG00000088862.1 across neuronal tissues (Fig. 5E,F), with
the exception of cerebellum and the cerebellar hemisphere,
potentially due to relatively lower levels of KCNQ5 and
CATG00000088862.1, whereas levels of RP11-398K22.12 re-
mained relatively higher. Additionally, we found an eQTL SNP
(rs14526472) overlappingwithRP11-398K22.12 and regulating ex-
pression of KCNQ5 in brain caudate (P=4.2 ×10−6; normalized ef-
fect size −0.58). All these findings indicate that RP11-398K22.12
is implicated in the nervous system bymaintaining the expression
of KCNQ5 and CATG000 00088862.1 in a cis-acting manner.
Discussion
This study systematically annotates lncRNAs through molecular
and cellular phenotyping by selecting 285 lncRNAs from human
dermal fibroblasts across a wide spectrum of expression, conserva-
tion levels and subcellular localization enrichments. Using ASO
technology allowed observed phenotypes to be associated to the
lncRNA transcripts, whereas, in contrast, CRISPR-based approach-
es may synchronically influence the transcription machinery at
the site of the divergent promoter or affect regulatory elements
of the targeted DNA site. Knockdown efficiencies obtained with
ASOs were observed to be independent of lncRNA expression lev-
els, subcellular localization, and of their genomic annotation, al-
lowing us to apply the same knockdown technology to various
classes of lncRNAs.
We investigated the cis-regulation of nearby divergent pro-
moters, which has been reported as one of the functional roles
of lncRNA (Luo et al. 2016). However, in agreement with previous
studies (Guttman et al. 2011), we did not observe general patterns
in the expression response of divergent promoters (Supplemental
Fig. S3B). Recent studies suggest that transcription of lncRNA loci
that do not overlap with other transcription units may influence
RNA polymerase II occupancy on neighboring promoters and
gene bodies (Engreitz et al. 2016a; Cho et al. 2018). Thus, it is plau-
sible that transcription of targeted lncRNA was maintained, de-
spite suppression of mature or nascent transcripts using ASOs.
This further suggests that the functional responses described in
this study are due to interference of processed transcripts present
either in the nucleus, the cytoplasm, or both. Although it is argu-
able that ASOs may interfere with general transcription by target-
ing the 5′-end of nascent transcripts and thus releasing RNA
polymerase II, followed by exonuclease-mediated decay and tran-
scription termination (aka “torpedo model”) (Proudfoot 2016),
most of the ASOs were designed across the entire length of the
transcript. Since we did not broadly observe dysregulation in near-
by genes, interference of transcription or splicing activity is less
likely to occur.
We observed a reduction in cell growth for ∼7.7% of our tar-
get lncRNA genes, which is in line with previous experiments us-
ing CRISPRi-pooled screening, which reported 5.9% (in iPS cells)
of lncRNAs exhibiting a cell growth phenotype (Liu et al. 2017).
Although these rates aremuch lower than for protein-coding genes
(Sokolova et al. 2017), recurrent observations of cell growth phe-
notypes (including cell death) strongly suggest that a substantial
fraction of lncRNAs play an essential role in cellular physiology
and viability. Further, when applying image-based analysis, we
found that lncRNAs affect cell morphologies (Fig. 2G), which has
not been so far thoroughly explored.
Several lncRNAs such as MALAT1, NEAT1, and FIRRE have
been reported to orchestrate transcription, RNA processing, and
gene expression (Kopp and Mendell 2018) but are not essential
for mouse development or viability. These observations advocate
for assays that can comprehensively profile the molecular changes
inside perturbed cells. Therefore, in contrast to cell-based assays,
functional elucidation via molecular phenotyping provides com-
prehensive information that cannot be captured by a single phe-
notypic assay. Herein, the number of overlapping differentially
expressed genes between two ASOs of the same lncRNA targets in-
dicated that 10.9% of lncRNAs exert a reproducible regulatory
function in HDF.
Although the features of selected lncRNAs are generally simi-
lar to those of other lncRNAs expressed in HDFs (Fig. 1B–D), the
cell-type-specific nature of lncRNAs and the relatively small sam-
pling size (119 lncRNAs with knockdown transcriptome profiles)
used in our study may not fully represent the whole extent of
lncRNA in other cell types. However, lncRNA targets that did not
exhibit amolecular phenotypemay be biologically relevant in oth-
er cell types or cell states (Li and Chang 2014; Liu et al. 2017). At
the same time, our results showed that particular lncRNAs ex-
pressed broadly in other tissues (e.g., in the human brain) were
functional in HDFs (such as RP11-398K22.12). Although the exact
molecularmechanisms of RP11-398K22.12 are not yet fully under-
stood, its potential role in HDFs suggests that lncRNAs may be
functionally relevant across multiple tissues in spite of the cell-
type-specific expression of lncRNAs.
Further, we used siRNA technology to knockdown lncRNA
targets as a method for independent validation. When comparing
the transcriptomes perturbed by ASOs and siRNAs, concordance
was observed only for three out of nine lncRNAs. This discrepancy
is likely due to different modes of actions of the two technologies.
Whereas ASOs invoke RNaseH-mediated cleavage, primarily active
FANTOM6 pilot study
Genome Research 1067
www.genome.org
 Cold Spring Harbor Laboratory Press on August 20, 2020 - Published by genome.cshlp.orgDownloaded from 
in the nucleus, the siRNAs use the RNA-inducing silencing com-
plex (RISC) mainly active in the cytoplasm. LncRNAs are known
to function in specific subcellular compartments (Chen 2016)
and their maturity, secondary structures, isoforms, and functions
could be vastly different across compartments (Johnsson et al.
2013). Since the majority of functional lncRNAs are reported to
be inside the nucleus (Palazzo and Lee 2018; Sun et al. 2018),
ASO-mediated knockdowns, which mainly target nuclear RNAs,
E
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Figure 5. RP11-398K22.12 down-regulates KCNQ5 and CATG00000088862.1 in cis. (A) Changes in expression levels of detectable genes in the
same topologically associated domain (TAD) as RP11-398K22.12 based on Hi-C analysis. Both KCNQ5 and CATG00000088862.1 are down-reg-
ulated (P<0.05) upon the knockdown of RP11-398K22.12 by two independent ASOs in CAGE analysis (left) as further confirmed with RT-qPCR
(right). (B) (Top) Representation of the chromatin conformation in the 4-Mb region proximal to the TAD containing RP11-398K22.12, followed
by the locus gene annotation, CAGE, RNA-seq, and ATAC-seq data for native HDFs. (Bottom) Schematic diagram showing Hi-C predicted con-
tacts of RP11-398K22.12 (blue) and KCNQ5 (gray) (25-kb resolution, frequency≥5) in HDF cells. Red line indicates RP11-398K22.12 and KCNQ5
contact. (C) FISH image for RP11-398K22.12, suggesting proximal regulation. TUG1 FISH image (suggesting trans regulation) is included as a
comparison; (bar = 10 µm). (D) GTEx atlas across 54 tissues (N=9662 samples) shows relatively high expression levels of RP11-398K22.12 in 13
distinct brain regions samples (highlighted). (E) Expression correlation for RP11-398K22.12 and KCNQ5 in eight out of 13 distinct brain regions,
as highlighted in D. (F ) Expression correlation for RP11-398K22.12 and CATG00000088862.1 in eight out of 13 distinct brain regions, as high-
lighted in D.
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are generally more suitable for functional screenings of our
lncRNA (62% found in the nuclear compartment). Besides, the dy-
namics of secondary effects mediated by different levels of knock-
down from different technologies are likely to be observed as
discordance when considering the whole transcriptome, where
this kind of discordance has been reported previously (Stojic
et al. 2018). In contrast, in the MKI67 assay, where only a single
feature such as growth phenotype is assayed, siRNAknockdown re-
vealed higher reproducibility with ASO knockdown. This suggest-
ed that the growth phenotype might be triggered by different
specific pathways in ASO- and siRNA-knockdowns.
Previous studies suggest that lncRNAs regulate gene expres-
sion in trans epigenetically, via direct or indirect interaction with
regulators such as DNMT1 (Di Ruscio et al. 2013) or by directly
binding to DNA (triplex) (Mondal et al. 2015) or other RNA-bind-
ing proteins (Tichon et al. 2016). Analysis of cellular localization
by fractionation followed by RNA-seq and in situ hybridization
can indicate whether a given lncRNAmay act in trans by quantify-
ing its abundance in the nuclear soluble fraction as compared to
cytoplasm. Althoughmost lncRNAs in the nuclear soluble fraction
may affect pathways associated with chromatin modification, ad-
ditional experiments to globally understand their interaction part-
ners will elucidate the molecular mechanism behind trans-acting
lncRNAs (Li et al. 2017; Sridhar et al. 2017).
In summary, our study highlights the functional importance
of lncRNAs regardless of their expression, localization, and conser-
vation levels. Molecular phenotyping is a powerful and generally
more sensitive to knockdown-mediated changes platform to reveal
the functional relevance of lncRNAs that cannot be observed based
on the cellular phenotypes alone. With additional molecular pro-
filing techniques, suchasRNAduplexmaps in livingcells todecode
common structural motifs (Lu et al. 2016), and Oxford Nanopore
Technology (ONT) to annotate the full-length variant isoforms of
lncRNAs (Hardwick et al. 2019), the structure-to-functional rela-
tionship of lncRNAs may be elucidated further in the future.
Methods
Gene models and lncRNA target selections
The gene models used in this study were primarily based on the
FANTOM CAGE-associated transcriptome (CAT) at permissive
level as defined previously (Hon et al. 2017). From this merged as-
sembly, there were ∼2000 lncRNAs robustly expressed in HDFs
(TPM≥1). However, we selected lncRNA knockdown targets in
an unbiased manner to broadly cover various types of lncRNAs
(TPM≥0.2). Briefly, we first identified a list of the lncRNA genes
expressed in HDFs, with RNA-seq expression at least 0.5 fragments
per kilobase permillion andCAGE expression at least 1 tag permil-
lion. Then, we manually inspected each lncRNA locus in the
ZENBU genome browser for (1) its independence from neighbor-
ing genes on the same strand (if any), (2) support from RNA-seq
(for exons and splicing junctions) and CAGE data (for TSSs) of
its transcript models, and (3) support from histone marks at TSSs
for transcription initiation (H3K27ac) and along the gene body
for elongation (H3K36me3), from the Roadmap Epigenomics
Consortium (Roadmap Epigenomics Consortium et al. 2015). A
representative transcript model, which best represents the RNA-
seq signal, was manually chosen from each locus for design of an-
tisense oligonucleotides. In total, 285 lncRNA loci were chosen for
ASO suppression. Additional controls (NEAT1, protein coding
genes) (Supplemental Table S1) were added, including MALAT1
as an experimental control. For details, please refer to the
Supplemental Methods.
ASO design
ASOs were designed as RNase H-recruiting locked nucleic acid
(LNA) phosphorothioate gapmers with a central DNA gap flanked
by 2–4 LNA nucleotides at the 5′ and 3′ ends of the ASOs. For de-
tails, please refer to the Supplemental Methods.
Automated cell culturing, ASO transfection, and cell harvesting
Robotic automation (Hamilton) was established to provide a stable
environment and accurate procedural timing control for cell cul-
turing and transfection. In brief, trypsin-EDTA detachment, cell
number and viability quantification, cell seeding, transfection,
and cell harvesting were performed with automation. All transfec-
tionswere divided into 28 runs on aweekly basis. ASO transfection
was performed with duplication. In each run, there were 16 inde-
pendent transfections with ASO negative control A (NC_A,
Exiqon) and 16 wells transfected with an ASO targeting MALAT-
1 (Exiqon).
The HDF cells were seeded in 12-well plates with 80,000 cells
in each well 24 h prior to the transfection. A final concentration of
20 nM ASO and 2 µL Lipofectamine RNAiMAX (Thermo Fisher
Scientific) were mixed in 200 µL Opti-MEM (Thermo Fisher
Scientific). The mixture was incubated at room temperature for
5min and added to the cells, whichweremaintained in 1mL com-
plete medium. The cells were harvested 48 h posttransfection by
adding 200 µL RLT buffer from the RNeasy 96 kit (Qiagen) after
PBS washing. The harvested lysates were kept at −80°C. RNA was
extracted from the lysate for real-time quantitative RT-PCR
(Supplemental Methods).
ASO transfection for real-time imaging
The HDF cells were transfected manually in 96-well plates to facil-
itate high-throughput real-time imaging. The cells were seeded
24 h before transfection at a density of 5200 cells per well. A final
concentration of 20 nM ASO and 2 µL Lipofectamine RNAiMAX
(Thermo Fisher Scientific) were mixed in 200 µL Opti-MEM
(Thermo Fisher Scientific). After incubating at room temperature
for 5 min, 18 µL of the transfection mix was added to 90 µL com-
plete medium in each well. The ASOs were divided into 14 runs
and transfected in duplicate. Each plate accommodated six wells
of NC_A control, twowells ofMALAT1 ASO control, and twowells
of mock-transfection (Lipofectamine alone) control.
Phase-contrast images of transfected cells were captured every
3 h for 2 d with three fields per well by the Incucyte live-cell imag-
ing system (Essen Bioscience). The confluence in each fieldwas an-
alyzed by the Incucyte software. Themean confluence of eachwell
was taken along the timeline until the mean confluence of the
NC_A control in the same plate reached 90%. The growth rate in
each well was calculated as the slope of a linear regression. A nor-
malized growth rate of each replicate was calculated as the growth
rate divided by themean growth rate of the sixNC_A controls from
the same plate. Negative growth rate was derived when cells shrink
and/or detach. As these rates of cell depletion could not be normal-
ized by the rate of growth, negative values were maintained to in-
dicate severe growth inhibition. Student’s t-test was performed
between the growth rate of the duplicated samples and the six
NC_A controls, assuming equal variance.
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Cell morphology quantification
For each transfection, a representative phase-contrast image at a
single time point was exported from the Incucyte time-series.
These raw images were first transformed to probability maps of
cells by pixel classification using ilastik (1.3.2) (Berg et al. 2019).
The trained model was then applied to all images where the pre-
dicted probability maps of cells (grayscale, 16 bits tiff format)
were subsequently used for morphology quantification in
CellProfiler (3.1.5) (Carpenter et al. 2006). For details, please refer
to the Supplemental Methods.
MKI67 staining upon lncRNA knockdown
For the selected four lncRNA targets showing >25% growth inhibi-
tion, we used two siRNAs and two ASOs with independent se-
quences. The transfected cells were fixed by adding prechilled
70% ethanol and incubated at −20°C. The cells were washed
with FACS buffer (2% FBS in PBS, 0.05%NaN3) twice. FITC-conju-
gated MKI67 (20Raj1, eBioscience) was applied to the cells and
subjected to flow cytometric analysis. Knockdown efficiency by
siRNA was determined by real-time quantitative RT-PCR using
the same three primer pairs as for ASO knockdown efficiency.
For details, please refer to the Supplemental Methods.
Wound closure assay
TheHDF cells were transfectedwith 20nMASOas described earlier
in 12-well plates. The cells were replated at 24 h posttransfection
into a 96-well ImageLock plate (Essen BioScience) at a density of
20,000 cells per well. At 24 h after seeding, cells form a spatially
uniform monolayer with 95%–100% cell confluence. The cells
were incubated with 5 µg/mL mitomycin C for 2 h to inhibit cell
division. Then, medium was refreshed and a uniform scratch was
created in each well by the WoundMaker (Essen BioScience). The
closure of the wound was monitored by Incucyte live-cell imaging
system (Essen Bioscience) every 2 h for 24 h. The RNAwas harvest-
ed after the assay for real-time quantitative RT-PCR. For details,
please refer to the Supplemental Methods.
Cap analysis of gene expression (CAGE)
Fourmicrograms of purified RNAwere used to generate libraries ac-
cording to the nAnT-iCAGE protocol (Murata et al. 2014). For de-
tails, please refer to the Supplemental Methods.
Chromosome conformation capture (Hi-C)
Hi-C libraries were prepared essentially as described previously
(Lieberman-Aiden et al. 2009; Fraser et al. 2015a) with minor
changes to improve the DNA yield of Hi-C products (Fraser et al.
2015b). For details, please refer to the Supplemental Methods.
Data access
All raw andprocessed sequencing data generated in this study have
been submitted to the DNA Data Bank of Japan (DDBJ; https://
www.ddbj.nig.ac.jp/) under accession numbers DRA008311,
DRA008312, DRA008436, and DRA008511 or can be accessed
through the FANTOM6 project portal https://fantom.gsc.riken
.jp/6/datafiles. The analysis results can be downloaded from
https://fantom.gsc.riken.jp/6/suppl/Ramilowski_et_al_2020/data/
and interactively explored using our in-house portal https
://fantom.gsc.riken.jp/zenbu/reports/#FANTOM6.
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